Northern Trust
AVTX icon

Northern Trust’s Avalo Therapeutics AVTX Stock Holding History

Northern Trust’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$456K Sell
30,556
-1,648
-5% -$25.8K ﹤0.01% 3648
2025
Q4 		$585K Buy
32,204
+13,629
+73% +$230K ﹤0.01% 3604
2025
Q3 		$236K Sell
18,575
-4,098
-18% -$35.2K ﹤0.01% 3924
2025
Q2 		$113K Hold
22,673
– – ﹤0.01% 4085
2025
Q1 		$182K Hold
22,673
– – ﹤0.01% 3973
2024
Q4 		$168K Buy
+22,673
New +$242K ﹤0.01% 4036
2023
Q4 		– Sell
-45
Closed -$1.31K – 4478
2023
Q3 		$1.31K Hold
45
– – ﹤0.01% 4458
2023
Q2 		$3.85K Hold
45
– – ﹤0.01% 4518
2023
Q1 		$19K Hold
45
– – ﹤0.01% 4458
2022
Q4 		$54.7K Hold
45
– – ﹤0.01% 4263
2022
Q3 		$36K Buy
45
+5
+13% +$5.42K ﹤0.01% 4411
2022
Q2 		$58K Sell
40
-146
-78% -$195K ﹤0.01% 4365
2022
Q1 		$388K Buy
186
+1
+0.5% +$2.51K ﹤0.01% 3840
2021
Q4 		$907K Buy
185
+5
+3% +$30K ﹤0.01% 3580
2021
Q3 		$1.13M Sell
180
-33
-15% -$267K ﹤0.01% 3512
2021
Q2 		$2.01M Buy
213
+26
+14% +$218K ﹤0.01% 3352
2021
Q1 		$1.62M Buy
187
+12
+7% +$113K ﹤0.01% 3360
2020
Q4 		$1.33M Buy
175
+11
+7% +$76.4K ﹤0.01% 3394
2020
Q3 		$1.07M Buy
164
+41
+33% +$308K ﹤0.01% 3368
2020
Q2 		$920K Buy
123
+25
+26% +$181K ﹤0.01% 3386
2020
Q1 		$703K Buy
98
+19
+24% +$201K ﹤0.01% 3352
2019
Q4 		$1.22M Sell
79
-2
-2% -$21.1K ﹤0.01% 3327
2019
Q3 		$769K Buy
81
+62
+326% +$692K ﹤0.01% 3459
2019
Q2 		$304K Buy
19
+6
+46% +$90.9K ﹤0.01% 3694
2019
Q1 		$222K Buy
13
+6
+86% +$89.8K ﹤0.01% 3752
2018
Q4 		$65K Buy
7
+2
+40% +$22.3K ﹤0.01% 4000
2018
Q3 		$63K Hold
5
– – ﹤0.01% 4105
2018
Q2 		$59K Sell
5
-6
-55% -$71.5K ﹤0.01% 4100
2018
Q1 		$135K Buy
11
+7
+175% +$78.9K ﹤0.01% 3902
2017
Q4 		$36K Buy
+4
New +$17.2K ﹤0.01% 4102

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Northern Trust's AVTX Position: Q1 2026 in Review

Northern Trust reduced its Avalo Therapeutics (AVTX) stake by 5.1% in Q1 2026, selling an estimated $25.8K and leaving 30,556 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #3648.

Northern Trust first reported a position in AVTX in Q4 2017 and has held it in 30 quarters since. The position peaked at $2.01M in Q2 2021. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Northern Trust held 30,556 shares of Avalo Therapeutics worth $456K as of Q1 2026.
  • Northern Trust sold 1,648 Avalo Therapeutics shares in Q1 2026, an estimated $25.8K.
  • Avalo Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3648 holding.
  • Northern Trust first reported a position in Avalo Therapeutics in Q4 2017 and has held it in 30 quarters since.
  • Northern Trust's Avalo Therapeutics position peaked at $2.01M in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.